Ann-Kristin Afflerbach, Christian Rohrandt, Björn Brändl, Marthe Sönksen, Jürgen Hench, Stephan Frank, Daniela Börnigen, Malik Alawi, Martin Mynarek, Beate Winkler, Franz Ricklefs, Michael Synowitz, Lasse Dührsen, Stefan Rutkowski, Annika K Wefers, Franz-Josef Müller, Melanie Schoof, Ulrich Schüller
BACKGROUND: Molecular brain tumor diagnosis is usually dependent on tissue biopsies or resections. This can pose several risks associated with anesthesia or neurosurgery, especially for lesions in the brain stem or other difficult-to-reach anatomical sites. Apart from initial diagnosis, tumor progression, recurrence, or the acquisition of novel genetic alterations can only be proven by re-biopsies. METHODS: We employed Nanopore sequencing on cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) and analyzed copy number variations (CNV) and global DNA methylation using a random forest classifier...
August 25, 2023: Clinical Chemistry